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Background
About 50% of melanoma (MM) have BRAF V600 muta-
tion and BRAF inhibitors, such as vemurafenib and dabra-
fenib, have shown an high response rate (RR) and overall
survival (OS) improvement in BRAF-mutated MM
patients (pts). Pembrolizumab, a monoclonal antibody
anti-PD-1, has shown a significant improvement in RR
and OS as well, in both MM pts naïve and previously trea-
ted with ipilimumab. As an immunotherapy, pembrolizu-
mab should not be affected by BRAF mutational status
and the aim of our analysis is to verify whether pembroli-
zumab is active regardless the BRAF mutational status .
Methods
Inside the expanded access program (EAP), pembrolizu-
mab was given in pts progressing after ipilimumab at
dosage of 2 mg/kg every 3 weeks until PD or unaccepta-
ble toxicity. At our Institution 47 pts (25M, 22F) were
treated. The median age was 49 years (range 28-70). All
pts were stage M1c. 40 (85.1%) pts had cutaneous MM,
5 (10.6%) had ocular MM and 2 (4.3%) mucosal MM.
16 out of 47 (34%) had BRAF V600 mutation, and all
mutated pts were previously treated with BRAF inhibi-
tors as per protocol. In this retrospective analysis we
evaluated the correlation between BRAF mutational sta-
tus and response to pembrolizumab.
Results
Data on RR and progression free survival (PFS) are
available for all 47 pts enrolled in the EAP. From this
analysis we excluded ocular MM because it’s considered
a distinct entity with a different biology. Among the 16/
42 (38,1%) pts with BRAF mutation, RR was of 12.5%
(2/16) compared with a RR of 36.4% (9/26) observed in
BRAF wild-type cohort. The difference was not statisti-
cally significant (p 0.16). Disease control rate (DCR) in
pts with BRAF mutation resulted 18.6% (3/16) compared
with 65.4% DCR (17/26) of BRAF wild-type cohort. The
difference was statistically significant (p 0.005). Median
PFS of BRAF mutated pts was 3 months (range 2.3 –
3.7), while was not reached (2 – 8+) in BRAF wild-type
cohort. The difference resulted statistically significant
(p 0.001).
Conclusions
Previous BRAF inhibitors treatment may affect response
to pembrolizumab. Further studies are needed to verify
this very preliminary observation.
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